| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Super-selective intra-arterial platinum-based chemotherapy concurrent with low-dose-rate plaque brachytherapy in the treatment of retinoblastoma: A simulation study
Hesameddin Mostaghimi1, Foad Goli Ahmadabad2, Hadi Rezaei3
1 Department of Biomedical Physics and Engineering, School of Medicine; Advanced Health Technologies Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Medical Physics, School of Medicine, Jiroft University of Medical Sciences, Jiroft; Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3 Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Hadi Rezaei,
Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran
Iran
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jcrt.JCRT_340_19
|
|
|
Objective: Retinoblastoma is the most common cancer among children under 5 years of age. The common conventional methods for the treatment of retinoblastoma include chemotherapy and brachytherapy (BT). This study investigated the concurrent use of BT with125 I and103 Pd sources and chemotherapy with platinum-based chemotherapy drugs for retinoblastoma.
Materials and Methods: The absorbed doses in different parts of the eye were measured with and without platinum. Platinum concentrations of 5, 7.5, 10, and 15 mg/g were evaluated, and the dose enhancement factors (DEFs) were calculated for different cases.
Results: For the125 I source, the DEFs at the tumor apex were 1.49, 1.67, 1.81, and 1.97 at concentrations of 5, 7.5, 10, and 15 mg/g, respectively. The DEF decreased dramatically beyond the apex at 0.85 cm from tumor base and was 0.87, 0.82, 0.76, and 0.63 for the abovementioned concentrations, respectively. For the103 Pd source, the DEFs were 1.15, 1.24, 1.21, and 1.07, respectively, at the apex and 0.76, 0.65, 0.56, and 0.39, respectively, beyond the apex.
Conclusions: Our results showed that the concurrent use of low-dose-rate plaque BT and platinum-based chemotherapy significantly increased the tumor-absorbed dose and decreased the absorbed dose in areas outside the tumor and the treatment time.
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 424 | | | PDF Downloaded | 8 |
|
Search Pubmed for